Convalife Pharmaceuticals Co. Ltd. has synthesized new polysubstituted aminoquinoline compounds acting as ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 (CD38) inhibitors potentially useful for the treatment of immunological disorders and cancer.